tiprankstipranks
Advertisement
Advertisement

FATE Stock Latest News

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
Company AnnouncementsFate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
3d ago
8K
FATE
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
PremiumRatings
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
3d ago
FATE
Fate Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Fate Therapeutics management to meet with Piper Sandler
4d ago
FATE
5 Healthcare Stocks Set to Join the Russell 3000
PremiumMarket News
5 Healthcare Stocks Set to Join the Russell 3000
12d ago
QSI
AGEN
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
PremiumWeekend Updates
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
15d ago
AMT
CTMX
Fate Therapeutics price target raised to $2.20 from $2 at BofA
PremiumThe FlyFate Therapeutics price target raised to $2.20 from $2 at BofA
16d ago
FATE
Fate Therapeutics assumed with a Buy at Jefferies
Premium
The Fly
Fate Therapeutics assumed with a Buy at Jefferies
19d ago
FATE
Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies
Premium
Ratings
Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies
25d ago
FATE
Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks
PremiumRatings
Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks
25d ago
FATE
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
PremiumThe Fly
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
25d ago
FATE
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright
PremiumThe Fly
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright
1M ago
FATE
FATE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
FATE Upcoming Earnings Report: What to Expect?
1M ago
FATE
Fate Therapeutics announces data presentation of FT839
PremiumThe FlyFate Therapeutics announces data presentation of FT839
2M ago
FATE
Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
Premium
Ratings
Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
3M ago
FATE
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
Premium
The Fly
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
3M ago
FATE
Fate Therapeutics presents updated Phase 1 data of FT819
PremiumThe Fly
Fate Therapeutics presents updated Phase 1 data of FT819
6M ago
FATE
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
PremiumCompany Announcements
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
7M ago
FATE
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
PremiumCompany Announcements
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
7M ago
FATE
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
PremiumRatings
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
7M ago
FATE
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
PremiumThe FlyFate Therapeutics reports Q3 EPS (27c), consensus (28c)
7M ago
FATE
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
7M ago
FATE
Is FATE a Buy, Before Earnings?
Premium
Pre-Earnings
Is FATE a Buy, Before Earnings?
7M ago
FATE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >